Physician profile
Jaclyn A Chomsky
NPI 1659612968
$3,101.96
in general payments reported to CMS, 2019-2025
22 companies · $596 in 2025
The $596 reported for 2025 was more than what 76% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $602 · 2022: $464 · 2023: $712 · 2024: $727 · 2025: $596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,036.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,035.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shockwave Medical, INC | $422.91 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Edwards Lifesciences Corporation | $356.24 | 2022-2025 | Sapien 3 Ultra Resilia |
| Viiv Healthcare Company | $349.17 | 2021-2025 | Dovato |
| Lilly USA, LLC | $345.44 | 2021-2025 | Mounjaro, Zepbound |
| Gilead Sciences, INC. | $280.72 | 2021-2025 | |
| Abbott Laboratories | $270.57 | 2023 | Mitraclip, Diamondback Peripheral |
| Glaxosmithkline, LLC. | $248.24 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Janssen Biotech, INC. | $196.67 | 2021-2023 | Symtuza |
| Medtronic, INC. | $160.64 | 2021 | |
| Novo Nordisk INC | $78.36 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $75.00 | 2021 | |
| Sanofi-Aventis U.S. LLC | $72.00 | 2021-2022 | |
| Astellas Pharma US INC | $39.84 | 2023-2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.82 | 2021-2023 | Jardiance |
| Pfizer INC. | $31.43 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $30.00 | 2021 | |
| Abiomed | $25.52 | 2024 | Impella |
| Exact Sciences Corporation | $22.60 | 2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $16.14 | 2023 | Xarelto |
| Phadia US INC. | $15.26 | 2025 | Immunocap |
| Astrazeneca Pharmaceuticals Lp | $15.13 | 2024 | Breztri |
| Theratechnologies INC. | $14.26 | 2023 | Trogarzo, Egrifta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaclyn Chomsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.